Although MUC1 loaded-DC vaccines have shown beneficial outcomes for patients with non-small cell lung cancer (84), peptide-loaded DC-vaccines have failed to show any superiority over the administration of ipilimumab, CTLA-4 targeting antibody, in melanoma patients (164). This evidence concerns the gene MUC1 and melanoma.